Core Viewpoint - Four Seasons Pharmaceutical (00460) reported a significant increase in revenue and profit for the first half of 2025, driven primarily by its aesthetic medicine business, leading to a rise in stock price by over 4% [1] Financial Performance - Revenue for the first half of 2025 reached 1.146 billion RMB, representing a year-on-year increase of 20.69% [1] - Shareholder profit amounted to 103 million RMB, marking a turnaround from a loss to profit [1] - The company proposed an interim cash dividend of 0.99 cents per share [1] Business Segment Performance - The aesthetic medicine segment generated approximately 585 million RMB in revenue, reflecting a year-on-year increase of about 81.3% [1] - This growth was attributed to strategic partnerships and a successful marketing strategy upgrade for the company's aesthetic platform, Meiyan Space [1] - Meiyan Space achieved breakthroughs in the regenerative field with the approval of two self-developed injection products: polycaprolactone microsphere facial filler (referred to as "girl's needle") and polylactic acid facial filler (referred to as "youth needle") [1]
港股异动 | 四环医药(00460)午后涨超4% 上半年扭亏为盈赚1.03亿元 医美业务收益大增